Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia
Background and Objectives: Hypertensive disorders of pregnancy remain one of the leading causes of morbidity and mortality in maternal–fetal medicine worldwide, particularly in low-resource settings. Despite extensive research in the last decades, pre-eclampsia prediction and, thus, effective preven...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/10/12/2474 |
| _version_ | 1797457557711749120 |
|---|---|
| author | Oana Balint Cristina Secosan Laurențiu Pirtea |
| author_facet | Oana Balint Cristina Secosan Laurențiu Pirtea |
| author_sort | Oana Balint |
| collection | DOAJ |
| description | Background and Objectives: Hypertensive disorders of pregnancy remain one of the leading causes of morbidity and mortality in maternal–fetal medicine worldwide, particularly in low-resource settings. Despite extensive research in the last decades, pre-eclampsia prediction and, thus, effective prevention remains an unsolved problem. Current evidence suggests that CA-125, an already recognised tumoral marker and, lately, a valuable severity marker of heart failure, can be used to evaluate pre-eclampsia severity and thus improve the identification and management of high-risk patients; Materials and Methods: This is a case–control study involving 100 pregnant patients over 25 weeks of gestation, grouped based on the severity of hypertension in gestational hypertension (n = 22), non-severe pre-eclampsia (n = 11), severe pre-eclampsia (n = 17), and a control group (normotensive) (n = 50). Clinical and biochemical parameters recommended by the international guidelines for evaluating hypertensive pregnant patients were gathered from every patient in addition to CA-125 levels. The correlation was analysed. Results: Mean CA-125 levels increased with the severity of hypertension from a mean of 8.97 U/mL (±2.84) in the normotensive group to a mean of 21.23 U/mL (±11.18) in the severe pre-eclampsia group. Significant differences were observed between each group. The correlation of CA-125 levels with the assessed clinical and biochemical parameters showed positive correlations with MAP, 24 h proteinuria, and LDH values and negative correlations with platelet count, gestational age at birth, and birth weight Conclusions: The reported results support this marker’s promising role as a severity marker and its potential to improve pre-eclampsia management allowing a better selection of high-risk patients, aiding in decision making related to hospitalisation and/or timing of birth. Further studies are needed to improve the accuracy of the obtained results, identify an accurate cut-off and an optimal time of measurement, and achieve standardisation in measuring the marker. |
| first_indexed | 2024-03-09T16:23:45Z |
| format | Article |
| id | doaj.art-8d72538a32914962a0884f127773e64a |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-09T16:23:45Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-8d72538a32914962a0884f127773e64a2023-11-24T15:10:39ZengMDPI AGHealthcare2227-90322022-12-011012247410.3390/healthcare10122474Role of CA-125 Level as a Marker in the Management of Severe Pre-EclampsiaOana Balint0Cristina Secosan1Laurențiu Pirtea2Department of Obstetrics and Gynecology, University of Medicine and Pharmacy “Victor Babes”, 300041 Timisoara, RomaniaDepartment of Obstetrics and Gynecology, University of Medicine and Pharmacy “Victor Babes”, 300041 Timisoara, RomaniaDepartment of Obstetrics and Gynecology, University of Medicine and Pharmacy “Victor Babes”, 300041 Timisoara, RomaniaBackground and Objectives: Hypertensive disorders of pregnancy remain one of the leading causes of morbidity and mortality in maternal–fetal medicine worldwide, particularly in low-resource settings. Despite extensive research in the last decades, pre-eclampsia prediction and, thus, effective prevention remains an unsolved problem. Current evidence suggests that CA-125, an already recognised tumoral marker and, lately, a valuable severity marker of heart failure, can be used to evaluate pre-eclampsia severity and thus improve the identification and management of high-risk patients; Materials and Methods: This is a case–control study involving 100 pregnant patients over 25 weeks of gestation, grouped based on the severity of hypertension in gestational hypertension (n = 22), non-severe pre-eclampsia (n = 11), severe pre-eclampsia (n = 17), and a control group (normotensive) (n = 50). Clinical and biochemical parameters recommended by the international guidelines for evaluating hypertensive pregnant patients were gathered from every patient in addition to CA-125 levels. The correlation was analysed. Results: Mean CA-125 levels increased with the severity of hypertension from a mean of 8.97 U/mL (±2.84) in the normotensive group to a mean of 21.23 U/mL (±11.18) in the severe pre-eclampsia group. Significant differences were observed between each group. The correlation of CA-125 levels with the assessed clinical and biochemical parameters showed positive correlations with MAP, 24 h proteinuria, and LDH values and negative correlations with platelet count, gestational age at birth, and birth weight Conclusions: The reported results support this marker’s promising role as a severity marker and its potential to improve pre-eclampsia management allowing a better selection of high-risk patients, aiding in decision making related to hospitalisation and/or timing of birth. Further studies are needed to improve the accuracy of the obtained results, identify an accurate cut-off and an optimal time of measurement, and achieve standardisation in measuring the marker.https://www.mdpi.com/2227-9032/10/12/2474CA-125pregnancy-induced hypertensionpre-eclampsia |
| spellingShingle | Oana Balint Cristina Secosan Laurențiu Pirtea Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia Healthcare CA-125 pregnancy-induced hypertension pre-eclampsia |
| title | Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia |
| title_full | Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia |
| title_fullStr | Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia |
| title_full_unstemmed | Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia |
| title_short | Role of CA-125 Level as a Marker in the Management of Severe Pre-Eclampsia |
| title_sort | role of ca 125 level as a marker in the management of severe pre eclampsia |
| topic | CA-125 pregnancy-induced hypertension pre-eclampsia |
| url | https://www.mdpi.com/2227-9032/10/12/2474 |
| work_keys_str_mv | AT oanabalint roleofca125levelasamarkerinthemanagementofseverepreeclampsia AT cristinasecosan roleofca125levelasamarkerinthemanagementofseverepreeclampsia AT laurentiupirtea roleofca125levelasamarkerinthemanagementofseverepreeclampsia |